Inclusion Criteria:  All patients regardless of sex or race between the ages 18-100 with biopsy proven PTMC with a Bethesda V or VI pathology or indeterminate cytology on fine-needle aspiration cytology (FNAC) who are recommended for treatment (Bethesda III/IV). Solitary thyroid nodule <20mm in maximal dimension. No sonographic evidence of extrathyroidal invasion, lymph node metastases, or distant metastases. There must be at least 1 mm of normal tissue as a margin, without sonographic evidence of contact with the capsule.  Exclusion Criteria:  Patients with other histological types of thyroid malignancy other than papillary thyroid cancer such as medullary carcinoma, Proto-oncogene serine/threonine kinase (BRAF) or Telomerase reverse transcriptase (TERT) mutations Clinically apparent multicentricity Lesions larger than 20 mm in maximum diameter. Recurrent laryngeal nerve palsy. Extension of nodule to posterior thyroid capsule. Ultrasound or other imaging studies revealing cervical lymph node involvement or distant metastases. Pregnancy. Pacemaker. Previous RFA.